Palovarotene is an orally bioavailable, selective retinoic acid receptor gamma (RARγ) agonist developed for the treatment of fibrodysplasia ossificans progressiva (FOP), an exceptionally rare genetic disorder characterized by progressive heterotopic ossification. The pharmaceutical product containing palovarotene is marketed as Sohonos. The U.S. FDA approved palovarotene on August 16, 2023, for reducing the volume of new heterotopic ossification in adults and pediatric patients with FOP.
Palovarotene is a small-molecule retinoid with the molecular formula C27H30N2O2 and molecular weight 414.54 g/mol. Its CAS Registry Number is 410528-02-8. PubChem assigns palovarotene CID 10295295, while FDA's Global Substance Registration System identifies UNII 28K6I5M16G.
Palovarotene is chemically identified as:
4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid
Its chemical structure contains a benzoic acid moiety, an E-configured ethenyl linkage, a substituted tetrahydronaphthalene ring and a pyrazole-containing side chain. PubChem and ChEBI identify it as a benzoic acid, pyrazole, stilbenoid and tetralin-containing compound.
These identifiers are supported by PubChem, FDA GSRS and ChEBI records.
Palovarotene acts primarily as a selective agonist of retinoic acid receptor gamma (RARγ). RARγ belongs to the nuclear receptor family and regulates gene transcription in response to retinoid signaling.
In FOP, a gain-of-function mutation in the ACVR1/ALK2 bone morphogenetic protein receptor contributes to abnormal signaling and endochondral bone formation. Palovarotene activates RARγ and suppresses downstream signaling associated with chondrogenesis and heterotopic bone formation. The FDA describes inhibition of SMAD1/5/8 phosphorylation as part of this mechanism, ultimately reducing ALK2/SMAD-dependent chondrogenesis and osteocyte differentiation.
This mechanism makes palovarotene particularly relevant to pharmaceutical research involving:
FOP is a rare genetic disorder in which soft connective tissues can progressively transform into bone. Episodes of new heterotopic ossification may be associated with disease flare-ups and can progressively restrict movement.
Palovarotene was developed to reduce the formation and volume of new heterotopic ossification. The FDA's approved indication covers adults and pediatric patients aged 8 years and older for females and 10 years and older for males with FOP.
The approval represents an important application of selective RARγ agonism in the management of abnormal skeletal development and heterotopic bone formation.
The primary pharmaceutical application of palovarotene is the management of FOP-associated heterotopic ossification.
Relevant pharmaceutical and research applications include:
FDA describes palovarotene as an orally bioavailable retinoid with particular selectivity for the RARγ subtype.
Palovarotene is a chemically synthesized small-molecule pharmaceutical active ingredient. Pharmaceutical-grade manufacturing requires appropriate controls for synthesis, purification, crystallization, drying, packaging and analytical testing.
Important quality attributes can include:
FDA's chemistry, manufacturing and controls review for Sohonos confirms that the finished-product manufacturing process and in-process controls were evaluated as part of the regulatory review.
Analytical characterization of palovarotene API may include chromatographic and spectroscopic techniques.
Potential analytical methods include:
A commercial research reference lists palovarotene at ≥98% HPLC, but this is a product-specific research-grade value and should not be represented as a universal pharmacopoeial API acceptance limit.
Palovarotene is reported as a white to off-white solid. A current chemical reference reports a melting point of 249–252°C, while commercial research references report slightly different physical descriptions and solubility depending on material and testing conditions.
Reported research solubility values include approximately 25 mg/mL in DMSO, although other commercial references report different maximum concentrations. These differences are expected because solubility depends on experimental conditions, solid form and preparation method.
Therefore, DMSO solubility should be treated as a reference research value, not as a pharmaceutical release specification.
RARγ selectivity is a defining characteristic of palovarotene. Retinoic acid receptor signaling has important roles in cellular differentiation and skeletal development.
The selective RARγ activity of palovarotene provides the pharmacological basis for its investigation and clinical development in conditions involving abnormal endochondral bone formation.
The compound has also been investigated historically in other areas, including emphysema, but its established U.S. pharmaceutical indication is reduction of new heterotopic ossification associated with FOP.
Palovarotene received its first global approval in Canada in 2022 and subsequently received U.S. FDA approval in August 2023. FDA's orphan-drug database lists the approved indication and the August 16, 2023 marketing approval date.
The product is marketed in the United States as Sohonos and is supplied as oral capsules in strengths of:
The FDA label identifies palovarotene as the active ingredient in these capsules.
For commercial pharmaceutical production, palovarotene API should be assessed using validated analytical methods appropriate to the drug substance.
Typical quality-control areas include:
The EMA assessment report for the finished product indicates that palovarotene finished-product specifications included HPLC-UV identification, assay and degradation-product testing, although these finished-product controls should not be automatically converted into API acceptance limits.
A pharmaceutical-grade palovarotene manufacturer should have appropriate capabilities for controlled small-molecule synthesis, purification and analytical characterization.
Commercial API qualification may require:
Because no current public USP/IP/Ph. Eur. API monograph with universal numerical release limits was identified for palovarotene, unsupported values should not be presented as official pharmacopoeial specifications.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Assay (HPLC) | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Melting Point | 249–252°C |